Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...
American Association of Individual Investors1d
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
PMLiVE1d
Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
manilatimes2d
MDA Launches 75th Anniversary Campaign and Premieres New PSA to Shine a Light on Rare Diseases
MDA launches 75th Anniversary campaign and premieres new public service announcement (PSA) to mark 75 years of impact in the ...
SMA3d
Spinal cord gray matter may be imaging marker of SMA types 2, 3
More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...
standardmedia.co.ke4d
Battle against the body's own nerves: How Motor Neurone Disease alters lives
MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.
People with spinal muscular atrophy demand urgent action from the Centre to reduce medicine costs
Health activists demand government action to reduce the cost of SMA medicines, citing constitutional obligations and ...
Pharm Exec6d
Biogen Seeks FDA Approval for a Higher Dosing Regimen of Spinraza for Spinal Muscular Atrophy
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
The Week6d
Spinal muscular atrophy: Patients, activists seek health ministry’s intervention to bring down medicine cost
The health activists argue that the government is empowered with effective law and policy tools and therefore should ...
SMA6d
US, EU regulators to review higher-dose Spinraza for use in SMA
Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...
Pharmabiz6d
Centre abdicates its constitutional obligation, criticises patients and experts on SMA issue
Centre abdicates its constitutional obligation, criticises patients and experts on SMA issue: Our Bureau, New Delhi Friday, January 24, 2025, 18:15 Hrs [IST] Patients and public h ...